<DOC>
	<DOCNO>NCT00873041</DOCNO>
	<brief_summary>CICL670A2209 : This study evaluate safety efficacy deferasirox non-transfusion dependent thalassemia patient iron overload . Patients treat either active treatment ( deferasirox ) placebo 12 month ( core study phase ) . Patients complete core study phase offer continue study active treatment ( deferasirox ) 12 month extension phase . During core extension , effect treatment iron overload liver evaluate use magnetic resonance imaging ( MRI ) assessment . CICL670A2209E1 : A one-year open-label extension randomize , double-blind , placebo-controlled , phase II study evaluate efficacy safety deferasirox non-transfusion dependent thalassemia patient iron overload ( Thalassa ) .</brief_summary>
	<brief_title>Efficacy Safety Deferasirox Non-transfusion Dependent Thalassemia Patients With Iron Overload One Year Open-label Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Core Male female age ≥ 10 year nontransfusion dependent syndrome , require transfusion within 6 month prior study start . Note : local country amendment Greece change age specific inclusion criterion ≥ 18 year old Liver iron concentration ≥ 5 mg/g dry weight measure Magnetic resonance imaging ( MRI ) study start Serum ferritin &gt; 300 ng/mL screen Core Hemoglobin S ( HbS ) variant thalassemia syndrome Anticipated regular transfusion program study . Patients sporadic transfusion ( e.g . case infection ) throughout study course exclude Any blood transfusion 6 month prior study start Creatinine clearance ≤ 60 mL/min screen Serum creatinine upper limit normal screen visit Significant proteinuria indicate urine protein/urine creatinine ratio &gt; 1.0 mg/mg Alanine aminotransferase ( ALT ) &gt; 5 x upper limit normal screen visit Concomitant therapy hydroxyurea , erythropoietin , butyrate History deferasirox treatment Pediatric patient : patient 's weight 20 kg Extension Patients complete core CICL670A2209 clinical trial Written inform consent obtain prior entry one year extension study CICL670A2209 Extension Patients continuous increase serum creatinine ≥ 33 % baseline value &gt; ULN improve drug interruption dose reduction core study Patients continuous increase ALT great 2 time baseline value &gt; 5 time ULN improve drug interruption dose reduction core study Patients progressive proteinuria , assess investigator , improve drug interruption dose reduction core study Significant medical condition interfere ability partake study ( e.g.systemic uncontrolled hypertension , unstable cardiac disease control standard medical therapy , systemic disease ( cardiovascular , renal , hepatic , etc . ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Thalassemia</keyword>
	<keyword>thalassemia intermedia</keyword>
	<keyword>alpha-thalassemia</keyword>
	<keyword>beta-thalassemia</keyword>
	<keyword>deferasirox</keyword>
	<keyword>iron overload</keyword>
	<keyword>non-transfusion dependent</keyword>
</DOC>